001     135967
005     20240229111723.0
024 7 _ |a pmid:88564
|2 pmid
024 7 _ |a 0099-5355
|2 ISSN
024 7 _ |a 0140-6736
|2 ISSN
024 7 _ |a 1474-547X
|2 ISSN
037 _ _ |a DKFZ-2018-00704
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Ricci, Cristian
|b 0
245 _ _ |a Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study.
260 _ _ |a London
|c 2018
|b British Medical Association56099
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1550485311_679
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To investigate the association between alcohol consumption (at baseline and over lifetime) and non-fatal and fatal coronary heart disease (CHD) and stroke.Multicentre case-cohort study.A study of cardiovascular disease (CVD) determinants within the European Prospective Investigation into Cancer and nutrition cohort (EPIC-CVD) from eight European countries.32 549 participants without baseline CVD, comprised of incident CVD cases and a subcohort for comparison.Non-fatal and fatal CHD and stroke (including ischaemic and haemorrhagic stroke).There were 9307 non-fatal CHD events, 1699 fatal CHD, 5855 non-fatal stroke, and 733 fatal stroke. Baseline alcohol intake was inversely associated with non-fatal CHD, with a hazard ratio of 0.94 (95% confidence interval 0.92 to 0.96) per 12 g/day higher intake. There was a J shaped association between baseline alcohol intake and risk of fatal CHD. The hazard ratios were 0.83 (0.70 to 0.98), 0.65 (0.53 to 0.81), and 0.82 (0.65 to 1.03) for categories 5.0-14.9 g/day, 15.0-29.9 g/day, and 30.0-59.9 g/day of total alcohol intake, respectively, compared with 0.1-4.9 g/day. In contrast, hazard ratios for non-fatal and fatal stroke risk were 1.04 (1.02 to 1.07), and 1.05 (0.98 to 1.13) per 12 g/day increase in baseline alcohol intake, respectively, including broadly similar findings for ischaemic and haemorrhagic stroke. Associations with cardiovascular outcomes were broadly similar with average lifetime alcohol consumption as for baseline alcohol intake, and across the eight countries studied. There was no strong evidence for interactions of alcohol consumption with smoking status on the risk of CVD events.Alcohol intake was inversely associated with non-fatal CHD risk but positively associated with the risk of different stroke subtypes. This highlights the opposing associations of alcohol intake with different CVD types and strengthens the evidence for policies to reduce alcohol consumption.
536 _ _ |a 323 - Metabolic Dysfunction as Risk Factor (POF3-323)
|0 G:(DE-HGF)POF3-323
|c POF3-323
|f POF III
|x 0
588 _ _ |a Dataset connected to PubMed,
650 _ 7 |a Urea
|0 8W8T17847W
|2 NLM Chemicals
700 1 _ |a Wood, Angela
|b 1
700 1 _ |a Muller, David
|b 2
700 1 _ |a Gunter, Marc J
|b 3
700 1 _ |a Agudo, Antonio
|b 4
700 1 _ |a Boeing, Heiner
|b 5
700 1 _ |a van der Schouw, Yvonne T
|b 6
700 1 _ |a Warnakula, Samantha
|b 7
700 1 _ |a Saieva, Calogero
|b 8
700 1 _ |a Spijkerman, Annemieke
|b 9
700 1 _ |a Sluijs, Ivonne
|b 10
700 1 _ |a Tjønneland, Anne
|b 11
700 1 _ |a Kyrø, Cecilie
|b 12
700 1 _ |a Weiderpass, Elisabete
|b 13
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 14
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 15
|u dkfz
700 1 _ |a Sánchez, Maria-Jose
|b 16
700 1 _ |a Panico, Salvatore
|b 17
700 1 _ |a Agnoli, Claudia
|b 18
700 1 _ |a Palli, Domenico
|b 19
700 1 _ |a Tumino, Rosario
|b 20
700 1 _ |a Engström, Gunnar
|b 21
700 1 _ |a Melander, Olle
|b 22
700 1 _ |a Bonnet, Fabrice
|b 23
700 1 _ |a Boer, Jolanda M A
|b 24
700 1 _ |a Key, Timothy J
|b 25
700 1 _ |a Travis, Ruth C
|b 26
700 1 _ |a Overvad, Kim
|b 27
700 1 _ |a Verschuren, W M Monique
|b 28
700 1 _ |a Quirós, J Ramón
|b 29
700 1 _ |a Trichopoulou, Antonia
|b 30
700 1 _ |a Papatesta, Eleni-Maria
|b 31
700 1 _ |a Peppa, Eleni
|b 32
700 1 _ |a Iribas, Conchi Moreno
|b 33
700 1 _ |a Gavrila, Diana
|b 34
700 1 _ |a Forslund, Ann-Sofie
|b 35
700 1 _ |a Jansson, Jan-Håkan
|b 36
700 1 _ |a Matullo, Giuseppe
|b 37
700 1 _ |a Arriola, Larraitz
|b 38
700 1 _ |a Freisling, Heinz
|b 39
700 1 _ |a Lassale, Camille
|b 40
700 1 _ |a Tzoulaki, Ioanna
|b 41
700 1 _ |a Sharp, Stephen J
|b 42
700 1 _ |a Forouhi, Nita G
|b 43
700 1 _ |a Langenberg, Claudia
|b 44
700 1 _ |a Saracci, Rodolfo
|b 45
700 1 _ |a Sweeting, Michael
|b 46
700 1 _ |a Brennan, Paul
|b 47
700 1 _ |a Butterworth, Adam S
|b 48
700 1 _ |a Riboli, Elio
|b 49
700 1 _ |a Wareham, Nick J
|b 50
700 1 _ |a Danesh, John
|b 51
700 1 _ |a Ferrari, Pietro
|b 52
773 _ _ |g Vol. 2, no. 8134
|0 PERI:(DE-600)1476593-7
|p k934
|t The @BMJ
|v 361
|y 2018
|x 0140-6736
909 C O |p VDB
|o oai:inrepo02.dkfz.de:135967
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-323
|2 G:(DE-HGF)POF3-300
|v Metabolic Dysfunction as Risk Factor
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 40
|0 StatID:(DE-HGF)9940
|2 StatID
|b LANCET : 2015
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21